The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


FDA extends review period for Novartis? multiple myeloma investigational compound LBH589.....           Amgen and AstraZeneca report positive Phase III trial results of plaque psoriasis drug brodalumab.....           Inergetics' advisory board meets to discuss launch preparations for new CBD-Based supplement line.....           Trimel announces issuance of additional patent covering NATESTO.....           Valeant gets FDA approval for ONEXTON gel to treat acne vulgaris.....           Paragon wins NIH contract to design and scale-up manufacturing of rhE-Selectin protein.....           Perrigo submits patent challenge for generic version of Aveed injection.....           Bristol-Myers, Five Prime to evaluate nivolumab and FPA008 combination in six tumor types.....           Celgene gets positive CHMP opinion for OTEZLA to treat psoriasis and psoriatic arthritis.....           Omnicare and McKesson expand distribution agreement.....           Merck, NewLink Genetics ink licensing deal for investigational Ebola vaccine.....           Transposagen enters into research collaboration with Janssen for Allogeneic CAR T-Cell therapies.....           Nuvilex forms Diabetes consortium to develop treatment for Insulin-Dependent Diabetes.....           BioMarin agrees to acquire Prosensa.....           Perrigo launches generic version of Astellas' Protopic ointment 0.1% and 0.03%.....           Amgen terminates all company-sponsored trials of rilotumumab in advanced gastric cancer.....           Which Allergan execs will stay? Actavis won't say, but promises job cuts, China growth.....           Novo Nordisk shrinks executive team as top-ranking woman leaves.....           Takeda's U.S. chief bows out amid management shake-up.....           Bayer may hive off another unit as it doubles down on pharma, consumer health.....           AstraZeneca, Ranbaxy unable to kill Nexium pay-for-delay lawsuit.....           With Duaklir nod in EU, AstraZeneca scores first new drug from Almirall buyout.....           FDA adds PML death scenario to Tecfidera label.....           AstraZeneca's Duaklir Genuair gets marketing approval in Europe for COPD.....           European Commission approves Novartis' Signifor to treat patients with acromegaly.....           Sevion, Avidity NanoMedicines enter research agreement for chimerasome.....           CHMP grants positive opinions of AbbVie's VIEKIRAX + EXVIERA to treat chronic hepatitis C.....           Orexigen gets allowance from USPTO for new US patent for Contrave.....           ZS Pharma reports results from Phase III study of ZS-9 in patients with hyperkalemia.....           EISAI launches antiepileptic drug fycompa in Hong Kong.....           Intra-Cellular Therapies reports positive results from Phase I/II ITI-007 trial.....           Xenetic completes dosing patients in Phase II MyeloXen trial to treat multiple sclerosis.....           Lundbeck CEO exits in disgrace, endangering key new launches.....           Drug prices plus low reimbursements force cancer docs to sell out.....           AstraZeneca says a U.S. expansion is needed to realize pipeline potential.....           U.K. gatekeepers toughest on cancer meds--and getting tougher all the time.....           Bayer sees IPO cash as war chest for new consumer deals.....           GSK shareholders to vote on Novartis megadeal in December.....           EMA CHMP issues positive opinion for Boehringer's nintedanib to treat IPF.....           Novo Nordisk's Victoza gets CHMP positive opinion to treat adults with type 2 diabetes.....           Genzyme?s Cerdelga secures European CHMP positive opinion.....           Yabao, MRC Technology to develop new therapeutics in China for Parkinson's disease.....           AstraZeneca plans $200m investment to expand Frederick biologics manufacturing center.....           Neurotrope doses last Alzheimer's disease patient in Phase IIa trial of Bryostatin-1.....           Dr. Reddy?s launches OTC Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120mg extended-release tablets.....           Baxter recalls one lot of highly concentrated potassium chloride injection in US.....           Highland Therapeutics receives second notice of allowance for patent on Lead product.....           Heptares Orphan disease program awarded grant from UK Biomedical catalyst.....           Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals.....           Dr. Reddy?s launches OTC Fexofenadine Hydrochloride 60 g and Pseudoephedrine Hydrochloride 120mg extended-release tablets.....           Boehringer one step closer to challenging Roche in Europe with EMA IPF nod.....           Merck's Zetia results inflame debate over statin prescribing.....           Sanofi nears European Gaucher market shakeup with EMA recommendation.....           Merck in talks with NewLink to scale up Ebola vaccine production: Bloomberg.....           EMA, like FDA, says testosterone-raising drugs are not for lifestyle use.....           Navidea's sentinel lymph node detection agent Lymphoseek gets marketing approval in Europe.....           AXIM to build manufacturing facility for hemp-based products in Netherlands.....           Sanofi and Regeneron's atopic dermatitis drug receives FDA breakthrough therapy status.....           FDA approves Purdue Pharma's Hysingla ER with abuse-deterrent properties.....           Abbvie expands capabilities in Asia with new manufacturing facility in Singapore.....           Novavax' RSV F-protein nanoparticle vaccine gets FDA fast track status.....           Sunshine selects Lonza to manufacture anti-cancer drug Adva-27a.....           Otologic starts Phase I HNPN-1010 trial to treat hearing disorders.....           Janssen submits NDA for three-month paliperidone palmitate to treat schizophrenia in US.....           FDA grants fast track status for Merrimack's pancreatic cancer drug MM-398.....           Axxess Pharma gets approval to sell high potency Omega-3 fish oil supplement in Canada.....           FDA grants orphan drug status for BerGenBio's BGB324 to treat acute myeloid leukaemia.....           CDISC and TransCelerate announce availability of new standards for diabetes and cardiovascular disease.....           Cynapsus reports positive top-line results from CTH-105 phase II trial of APL-130277 to treat Parkinson's Disease.....           Amgen opens next-generation Biomanufacturing facility in Singapore.....           Medidata, TransCelerate report findings of joint research initiative on clinical trial site monitoring methods.....           Aspira to distribute Nagase's unnatural amino acids for next-generation drug candidate development.....           OnCore, Blumberg enter exclusive HBV research collaboration.....           So long, patent cliff. Hello, hep C and cancer. Welcome to $1.3T in global drug spending.....           Court shoots down Ranbaxy's bid to block rival Nexium and Valcyte generics.....           France strikes big hep C treatment deal for Gilead's Sovaldi.....           Which old meds hold their own with fast-growing Sovaldi, Tecfidera, and Xarelto? Try Humira and Revlimid.....           Why the Bexsero delay? Novartis holding government to 'ransom,' U.K. says.....           Can Sanofi parlay low Lantus prices into Toujeo sales? That's the billion-dollar question.....           FDA approves Purdue's abuse-resistant Hysingla, a hydrocodone pill aimed at knocking off Zohydro.....           CytRx gets FDA notice on partial clinical hold of aldoxorubicin clinical trials.....           Galena Biopharma closes enrollment in Phase II trial of GALE-401.....           NICE asks Novartis to pony up more information on Xolair for hives.....           Boehringer Ingelheim keeps rolling out data in support of anticoagulant Pradaxa.....           Solo Shire moves 500 to Boston as it pushes ahead with reorg.....           Warning to Takeda, Bayer, Novartis and AstraZeneca: CEO-hunting Sanofi may poach your executives.....           Novartis seeks tech partners for brave new beyond-the-pill world.....           Can't get through a doc's door, pharma reps? You may want to target mid-level pros.....           Bayer gets approval in Japan for Eylea to treat diabetic macular edema.....           Bayer gets approval in Japan for Eylea to treat diabetic macular edema.....           Pfizer launches meningococcal group B vaccine Trumenba in US.....           Pfizer launches meningococcal group B vaccine Trumenba in US.....           Gilead's hepatitis C drug Harvoni gets marketing authorization in Europe.....           Gilead's hepatitis C drug Harvoni gets marketing authorization in Europe.....           3SBio enters into license deal with PharmAbcine for Tanibirumab.....           3SBio enters into license deal with PharmAbcine for Tanibirumab.....           Aphios gets US patent for Nanotechnology co-encapsulation of combination drugs and drug products.....           Aphios gets US patent for Nanotechnology co-encapsulation of combination drugs and drug products.....           FDA allows Fibrocell's IND application for new Wounded Warrior Amputees to prevent stump skin diseases.....           FDA allows Fibrocell's IND application for new Wounded Warrior Amputees to prevent stump skin diseases.....           Alliance for Children?s Therapeutics to expand pediatric research to MS, IBD and asthma.....           Alliance for Children?s Therapeutics to expand pediatric research to MS, IBD and asthma.....           Edge Therapeutics enters research collaboration with leading academic medical center.....           Edge Therapeutics enters research collaboration with leading academic medical center.....           Intellia announces $15m in funding to develop therapeutic products using CRISPR-Cas9 Gene Editing Technology.....           Intellia announces $15m in funding to develop therapeutic products using CRISPR-Cas9 Gene Editing Technology.....           UPDATED: Has Allergan failure weakened Valeant CEO's M&A hand?.....           Novavax starts patient enrolment in Phase II trial of quadrivalent seasonal influenza VLP.....           Novavax starts patient enrolment in Phase II trial of quadrivalent seasonal influenza VLP.....           Cardiome inks commercialization deal with Aspen for Brinavess in South Africa.....           Cardiome inks commercialization deal with Aspen for Brinavess in South Africa.....           Actavis' merger cost-cutting isn't Valeant-style. But it's still $1.8B.....           Actavis' merger cost-cutting isn't Valeant-style. But it's still $1.8B.....           AstraZeneca's anti-Pfizer growth promises? At least one big investor is buying.....           AstraZeneca's anti-Pfizer growth promises? At least one big investor is buying.....           Has Allergan failure weakened Valeant CEO's M&A hand?.....           Has Allergan failure weakened Valeant CEO's M&A hand?.....           GSK, Novo earn top marks getting their meds to poor, but more work lies ahead.....           GSK, Novo earn top marks getting their meds to poor, but more work lies ahead.....           Ranbaxy sues FDA to protect its exclusive for generic Nexium.....           EU nod sets up Gilead's Harvoni for record-breaking sales.....           EU nod sets up Gilead's Harvoni for record-breaking sales.....           Pfizer, Merck to jointly develop and commercialize new cancer treatments.....           Actavis agrees to buy Botox-maker Allergan for $66bn.....           FDA approves trade name Auryxia for Keryx's ferric citrate.....           Teva gets Health Canada approval for generic Celebrex.....           OXiGENE gets European patent for OXi4503 in AML and other myeloid malignancies.....           Birmingham University gets grant to support human research on ChromaDex's NIAGEN Nicotinamide Riboside.....           RetroSense Therapeutics signs license deal with Massachusetts General Hospital.....           Kite Pharma gets positive opinion for orphan drug designation in Europe for cancer immunotherapy.....           Dicerna inks license agreement with Tekmira to advance PH1 development program.....           Genentech gets FDA approval for Avastin to treat ovarian cancer.....           Genticel closes patient enrolment in Phase II ProCervix trial.....           Bristol Myers reports positive Phase III trial results of melanoma drug Opdivo.....           Boehringer, WellPoint and HealthCore start new multi-year research collaboration.....           Actavis ready to leap into Big Pharma with $64B bid for Allergan.....           Surprise: Merck's cholesterol combo Vytorin hits goal in long-awaited outcomes trial.....           Reckitt ready to set pharma free in December spinoff, dubbed Indivior.....           FDA Commissioner to talk drug safety with top Chinese officials.....           Actavis officially steals Allergan from Valeant with $66B buyout.....           Generics makers, execs face potential criminal charges in U.S. pricing probe.....           Valeant and Allergan's wining-and-dining shows pharma's faith in doctor influence.....           Bristol Myers to build new large-scale biologics manufacturing plant in Ireland.....           FDA approves Genzyme?s Lemtrada to treat multiple sclerosis.....           Recipharm acquires Lusomedicamenta for SEK1bn.....           Merck reports positive Phase II trial results of melanoma drug pembrolizumab.....           UL Information & Insights launches online marketplace for Dietary Supplement Industry.....           BeiGene completes $75m financing.....           Alnylam reports positive initial phase II data with Revusiran to treat TTR Cardiac Amyloidosis.....           Cortice Biosciences reports initial results from a Phase I/II trial of TPI 287 to treat recurrent Glioblastoma.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
APS Freeze Drying and Alternative Drying Technologies for Parenterals
FRIDAY, 14 NOVEMBER 2014
Burleigh Court, Loughborough Wednesday 28th January 2015. The meeting is being organised jointly by two of the APS focus groups, Parenterals Focus Group and Biotherapeutics and Vaccines Focus Group. The meeting will look at the latest challenges and opportunities in the preservation of biopharmaceuticals. It will cover both conventional freeze drying but also look at alternative technologies such as spray drying and Super Critical Fluid (SCF) drying. There will be presentations on the:. Impact and selection of Process.. Analytical Technologies for freeze drying,. The incorporation of ice nucleation as at tool for shortening processing times and improving batch homogeneity.. Impact of formulation selection and the industrial application of spray drying in biotherapeutics.. Application of Super Critical Fluid drying in biotherapeutics.. Speakers will include:. Patrick Garidel (Boerringher Ingelheim, Germany), Geoff Smith (DeMontfort University), Kevin Ward, (Biopharma), Richard Kaye (GSK), Daryl Williams (Imperial University) Peter York (Crystec Pharma). There will also be an exhibitor’s showcase by companies working in this area. The event is suitable for both scientists and leaders in the pharmaceutical arena as well as other processing industries who have a particular interest in the formulation, processing and analysis of biopharmaceuticals.. For more information and to register, please visit us online at:. http://www.apsgb.co.uk/EVENTS/20150128/Default.asp. .
The European Paediatric Formulation Initiative (EuPFI) paediatric biopharmaceutics survey
WEDNESDAY, 22 OCTOBER 2014
The EuPFI (European Paediatric Formulation Initiative www.eupfi.org) are looking to gather the views of biopharmaceuics scientists on the development of a paediatric biopharmaceutics classification system.. If you are an individual working in the area of biopharmaceutics, we would really appreciate your time in completing this short survey. Note that we would like individuals to complete this based on their own opinions and not necessarily those of their employer. Feel free to share this with others working in this area.. xhttps://www.survey.bris.ac.uk/bham/eupfi-biopharm-bcs . We anticipated that this will take 10-15 minutes and we plan to share our findings via the EuPFI but please leave your contact details within the questionnaire if you would like a direct mail regarding the output.. With many thanks for your time. The EuPFI Biopharmaceutics workstream.
Information Webinar ITT Modular Masters Formulation Consortium
TUESDAY, 7 OCTOBER 2014
Interested in Delivering the Modular Masters in Formulation Science and Technology? Information Webinars for Providers 10th and 13th October. You may have already heard about the Science Industry Partnership (SIP) and the innovative new Modular Masters Programme in Formulation Science and Technology. If not, you will find further details on the SIP website: xhttp://www.scienceindustrypartnership.com/modular-masters/.. The process to select the provider or provider consortium which will deliver the full programme in collaboration with the SIP has now begun. There are opportunities for Higher Education Institutions (HEIs) as well as private sector and other educational providers to become involved. So if you are interested in finding out how you could become part of this exciting new programme then register now for one of our short briefing webinars to be held on Friday 10th October at 11.00 AM or Monday 13th October at 12.30 PM.. To register to attend, simply e-mail info@iformulate.biz with your full contact details and preferred webinar date. We will send webinar joining details to registrants ahead of time.. We expect the formal application process to open at the end of October and close at the end of November. Final selection of the provider or provider consortium will be made in early January 2015.. We will also be helping provider consortiums to form by sharing contact details and areas of expertise of interested parties. If you would like your details to be shared in this way, please provide (by e-mail to info@iformulate.biz) a short description of topics, expertise and existing or planned relevant educational provision. If you are considering leading a consortium, you may also wish to indicate in which areas you require partners to fill any gaps in provision.. We look forward to speaking with you at one of the webinars... Tina Roberts Higher Education Development Manager Cogent Sector Skills Council Unit 5 Mandarin Court Centre Park Warrington WA1 1GG. Tel: 01925 515200 x301 Mobile: 07715014099 Fax: 01925 515240 Email: tina.roberts@cogent-ssc.com Web: www.cogent-ssc.com.
Unique leadership event for women in healthcare science leadership
TUESDAY, 16 SEPTEMBER 2014
The Academy of Pharmaceutical Sciences (APS) and Royal Pharmaceutical Society (RPS) are organising a symposium on the 7 October 2014 for women in healthcare science leadership.. The organisers have put together a panel of leading professionals to help women develop their careers and includes eminent speakers from across clinical pharmacy, academic research and industry. The event is attracting a wide audience of individuals involved in leadership in the healthcare science and we would love to see you there.. . Are you looking to take the next step in your career? Are you ready to set new challenges and enhance your leadership skills?. Join us to hear from inspiring leaders in academic research, clinical pharmacy, and industry.. Helen Gordon, Chief Executive, Royal Pharmaceutical Society, says: “Our Women in healthcare science leadership symposium is a new event, developed to support women in existing or aspiring leadership roles. Attending will provide you with the perfect opportunity to challenge what you know about yourself and develop practical skills that will support your career. I for one am looking forward to hearing from our great line-up of speakers, who I’m sure will inspire and motivate you to excel and lead others in your field.”. The symposium has great networking potential with speakers from across clinical pharmacy, academic research and life sciences including:. Cathy Mooney MRPharmS, Deputy Director of Quality and Safety, University College London Hospitals NHS Foundation Trust Harriet Fear, CEO, One Nucleus Helena Morrissey CBE, CEO, Newton and Founder 30% Club Philippa Roberts MRPharmS, Director of Pharmacy and Risk Management, Wirral University Teaching Hospital NHS Foundation Trust Themes include leadership, innovation and entrepreneurship. During the day, you will:. Learn how to develop your leadership skills and successfully drive your career forwards Identify the successes and challenges for women in the workplace Discuss real life experiences with leading healthcare practitioners Examine the benefits of diversity in the workplace Learn how to overcome the barriers (both real and perceived) to becoming a leader Learn how to influence at the most senior level and to build networks. There will also be a Q&A session, giving you the unique opportunity to ask specific questions relating to your career.. We aim to provide you with the skills and confidence to successfully drive your career forward. Don't miss out: view the full programme and register today.. http://www.rpharms.com/conferences/women-in-healthcare-science-leadership -symposium.asputm_medium=email&utm_source=Royal+Pharmaceutical+Society &utm_campaign=4695578_Women+in+healthcare+event+-+generic&dm_i=EQ,2S N4Q,G415KU,A5V2J,1.
 
Follow us
 
Upcoming Events
APS Freeze drying and alternative drying technologies for parenterals
28 January 2015
APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.